Rectal Adenocarcinoma — Trials

Rectal Adenocarcinoma — Trials · CancerIndex

Clinical trials

Registered studies

187 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 52
Recruiting: 28
Ph III recruiting: 3
Growth YoY: —
Industry share: 2%
Top sponsor: M.D. Anderson Cancer Center
Termination share: 39.7%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (32)

clinicaltrialsPublishedShowing 1–7 of 7 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03992456	Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer	unknown	Phase 2	12	Academic and Community Cancer Research UnitedOTHER	1	May 21, 2024	clinicaltrials
NCT04621370	A Trial of Durvalumab (MEDI 4736) in Combination With Extended Neoadjuvant Regimens in Rectal Cancer(PRIME-RT)	unknown	Phase 2	48	Liz-Anne LewsleyOTHER	0	Nov 9, 2020